Anti-Apoptotic BCL-2 Family Proteins Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Documenti analoghi

• The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib Abrogates Bispecific Antibody-Mediated T-cell Cytotoxicity
  di: Godwin, Colin D., et al.
  Pubblicazione: (2020)
• The CD33 Splice Isoform Lacking Exon 2 as Therapeutic Target in Human Acute Myeloid Leukemia
  di: Godwin, Colin D., et al.
  Pubblicazione: (2020)
• Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330
  di: Laszlo, George S., et al.
  Pubblicazione: (2019)
• Cleavage behavior of calicheamicin gamma 1 and calicheamicin T.
  di: Walker, S, et al.
  Pubblicazione: (1992)
• Deregulation of Apoptotic Factors Bcl-xL and Bax Confers Apoptotic Resistance to Myeloid-derived Suppressor Cells and Contributes to Their Persistence in Cancer
  di: Hu, Xiaolin, et al.
  Pubblicazione: (2013)